The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1

被引:60
作者
Muthumani, K
Choo, AY
Zong, WX
Madesh, M
Hwang, DS
Premkumar, A
Thieu, KP
Emmanuel, J
Kumar, S
Thompson, CB
Weiner, DB [1 ]
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[3] Mem Sloan Kettering Canc Ctr, Lab Mol Neuropharmacol, New York, NY 10021 USA
关键词
D O I
10.1038/ncb1352
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The Vpr protein of HIV-1 functions as a vital accessory gene by regulating various cellular functions, including cell differentiation, apoptosis, nuclear factor of kappa B (NF-kappa B) suppression and cell-cycle arrest of the host cell. Several reports have indicated that Vpr complexes with the glucocorticoid receptor (GR), but it remains unclear whether the GR pathway is required for Vpr to function(1). Here, we report that Vpr uses the GR pathway as a recruitment vehicle for the NF-kappa B co-activating protein, poly(ADP-ribose) polymerase(1) (PARP-1). The GR interaction with Vpr is both necessary and sufficient to facilitate this interaction by potentiating the formation of a Vpr-GR-PARP-1 complex. The recruitment of PARP-1 by the Vpr-GR complex prevents its nuclear localization, which is necessary for Vpr to suppress NF-kappa B. The association of GR with PARP-1 is not observed with steroid (glucocorticoid) treatment, indicating that the GR association with PARP-1 is a gain of function that is solely attributed to HIV-1 Vpr. These data provide important insights into Vpr biology and its role in HIV pathogenesis.
引用
收藏
页码:170 / U48
页数:13
相关论文
共 34 条
[1]   Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation [J].
Arad, G ;
Levy, R ;
Hillman, D ;
Kaempfer, R .
NATURE MEDICINE, 2000, 6 (04) :414-421
[2]   HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B [J].
Ayyavoo, V ;
Mahboubi, A ;
Mahalingam, S ;
Ramalingam, R ;
Kudchodkar, S ;
Williams, WV ;
Green, DR ;
Weiner, DB .
NATURE MEDICINE, 1997, 3 (10) :1117-1123
[3]   The sequence-specific DNA binding of NF-κB is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1 [J].
Chang, WJ ;
Alvarez-Gonzalez, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (50) :47664-47670
[4]   Shaping the nuclear action of NF-κB [J].
Chen, LF ;
Greene, WC .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (05) :392-401
[5]   Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr [J].
de Noronha, CMC ;
Sherman, MP ;
Lin, HW ;
Cavrois, MV ;
Moir, RD ;
Goldman, RD ;
Greene, WC .
SCIENCE, 2001, 294 (5544) :1105-1108
[6]   Expression level-dependent contribution of glucocorticoid receptor domains for functional interaction with STAT5 [J].
Doppler, W ;
Windegger, M ;
Soratroi, C ;
Tomasi, J ;
Lechner, J ;
Rusconi, S ;
Cato, ACB ;
Almlof, T ;
Liden, J ;
Okret, S ;
Gustafsson, JÅ ;
Richard-Foy, H ;
Starr, DB ;
Klocker, H ;
Edwards, D ;
Geymayer, S .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (09) :3266-3279
[7]   Immunologic control of HIV-1 [J].
Gandhi, RT ;
Walker, BD .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :149-172
[8]   HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell [J].
Geleziunas, R ;
Xu, WD ;
Takeda, K ;
Ichijo, H ;
Greene, WC .
NATURE, 2001, 410 (6830) :834-838
[9]   HIV-1 Vpr increases viral expression by manipulation of the cell cycle:: A mechanism for selection of Vpr in vivo [J].
Goh, WC ;
Rogel, ME ;
Kinsey, CM ;
Michael, SF ;
Fultz, PN ;
Nowak, MA ;
Hahn, BH ;
Emerman, M .
NATURE MEDICINE, 1998, 4 (01) :65-71
[10]   The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function [J].
Hassa, PO ;
Covic, M ;
Hasan, S ;
Imhof, R ;
Hottiger, MO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (49) :45588-45597